Active	Status	Sponsor type	Region	Phase	Filter
5 Active 1 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Aldave, Anthony J
EXPEDE, NCT04081103: NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries	Terminated	2	35	US	Nexagon® (lufepirsen) High Dose Concentration, Nexagon® (lufepirsen) Low Dose Concentration, Vehicle, Placebo, Open-label Nexagon® (lufepirsen)	Amber Ophthalmics, Inc.	Corneal Persistent Epithelial Defect	02/22	02/22
NCT04627571: Corneal Nerves After Treatment With Cenegermin	Active, not recruiting	N/A	40	US	Cenegermin Ophthalmic Solution [Oxervate]	University of California, Los Angeles, Dompé Farmaceutici S.p.A	Neurotrophic Keratitis	02/25	02/25
Pascual, Ellen
EXPEDE, NCT04081103: NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries	Terminated	2	35	US	Nexagon® (lufepirsen) High Dose Concentration, Nexagon® (lufepirsen) Low Dose Concentration, Vehicle, Placebo, Open-label Nexagon® (lufepirsen)	Amber Ophthalmics, Inc.	Corneal Persistent Epithelial Defect	02/22	02/22